Sei Investments Co. Increases Holdings in Elanco Animal Health Incorporated $ELAN

Sei Investments Co. boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 737.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,650,393 shares of the company’s stock after purchasing an additional 4,975,721 shares during the quarter. Sei Investments Co.’s holdings in Elanco Animal Health were worth $135,214,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ELAN. Peak Retirement Planning Inc. bought a new position in Elanco Animal Health during the fourth quarter worth about $2,756,000. Norges Bank bought a new stake in Elanco Animal Health in the 4th quarter valued at about $32,415,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $3,947,000. BNP Paribas Financial Markets grew its position in shares of Elanco Animal Health by 3,682.0% during the 4th quarter. BNP Paribas Financial Markets now owns 2,252,961 shares of the company’s stock worth $50,985,000 after purchasing an additional 2,193,391 shares in the last quarter. Finally, OP Asset Management Ltd bought a new position in shares of Elanco Animal Health during the first quarter worth approximately $8,171,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday. JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.73.

Elanco Animal Health Stock Down 2.2%

ELAN stock opened at $24.78 on Friday. The stock has a market capitalization of $12.38 billion, a P/E ratio of -49.56, a price-to-earnings-growth ratio of 1.66 and a beta of 1.68. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72. The firm has a 50-day moving average price of $23.91 and a 200-day moving average price of $23.97.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm’s revenue was up 14.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.